Cytogen (217330.KQ) Stock Price

Cytogen Price

CLOSED
2,925.00
​
Market closed

Revenue at Cytogen has contracted by 23.5% per year over the past 11 years to 26.05 B KRW. Cytogen's net margin stands at -47.4%, up from -3,125.1% several years earlier.

Cytogen stock price

Access this data via the Eulerpool API

Cytogen business model & stock analysis

CytoGen, Inc. is a holding company which engages in the researche and development of cancer treatment solutions. The company is headquartered in Seoul, Seoul and currently employs 43 full-time employees. The company went IPO on 2018-11-22. The liquid biopsy application services include biomarker discovery and verification services, as well as liquid biopsy-based precision medical services which is the commercialization of companion diagnostics (CDx) development, among others. The biomarker discovery and verification services include circulating tumor cell (CTC)-based biomarker discovery and validation, gene mutation and transcript expression analysis, and drug testing and analysis services, among others. The liquid biopsy-based precision healthcare services include companion diagnosis, re-selection of therapeutic drugs, examination and treatment effectiveness monitoring, and recurrence prediction services, among others. In addition, the Company develops and sells platforms and kits for liquid biopsy. The firm distributes its products within the domestic market and to overseas markets.

Frequently asked questions about Cytogen

Converted at the current exchange rate, the Cytogen share trades at 1.95 EUR (2,925.00 KRW).

The revenue cannot currently be calculated for Cytogen.

The profit cannot currently be calculated for Cytogen.

The P/E ratio cannot be calculated for Cytogen at the moment.

The P/S cannot be calculated for Cytogen currently.

The Eulerpool Quality Score for Cytogen is 4/10.

The ISIN of Cytogen is KR7217330000. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Cytogen is 217330.KQ. The ticker symbol is used to trade Cytogen shares on the stock exchange.

Fair ValueTerminal
3,042.00 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
605.93 M KRW
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
South Korea
Currency
KRW
Initial public offering
Nov 22, 2018
ISIN
KR7217330000
Cusip
Y1R57W103
Market capitalization
67.66 B KRWLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
1.90
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-26.67 %
Last updated Oct 9, 2026, 3:02 AM

Cytogen Peer Group

Cytogen FIGI

217330:KS · BBG00M8WDQ37217330:KQ · BBG00M8WDQ55

All fundamentals and in-depth analysis of Cytogen

Our stock analysis for Cytogen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cytogen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.